Valneva Shares Surge 11.83% to €2.68, Marking the Strongest Rebound in the SBF 120
Valneva, a vaccine-specialized laboratory, records the highest rebound in the SBF 120 on Monday midday, climbing to €2.68, while the broader index drops by 0.85% during the session. This marks a significant recovery after several weeks of continuous decline.
Valneva leaps by 11.83% to €2.68, leading the SBF 120 at midday, ahead of Nanobiotix (+10.46%) and Teleperformance (+5.13%). The stock has gained 16.09% over the week but still shows a decline of 35.6% over three months. This session partially reverses the sharp drop observed at the end of April and beginning of May, following the completion of an €84 million capital raise on April 30, which had weighed on the stock price. Today's rebound occurs without any specific news from the group during the session. This movement goes against the trend of the CAC 40, which is down 0.96% at 8,034.88 points, and the SBF 120, which has fallen by 0.85%. It is worth recalling that the stock also suffered from a downgrade by Goldman Sachs to 'sell' on April 22, adding to an already heavy bearish sequence.
Exiting the Low Zone, Resistance at €2.85
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
The stock price has moved back above the MM20 at €2.46 (a +9.11% gap), but remains far from the MM50 at €3.32 and the MM200 at €3.87. Thus, the medium-term trend is still bearish, despite today's surge. The RSI at 36 has exited the oversold zone where it had been for several sessions. With the intraday rise, the stock approaches the upper Bollinger Band at €2.74, which is 90% of the amplitude, and heads towards the technical resistance identified at €2.85. Breaking through this threshold would open the way towards the MM50. On the calendar side, the laboratory will participate in the Bernstein European Small & Mid-Cap Conference on May 21, before two general meetings scheduled for June 1 and June 25. The first quarter 2026 results, initially expected on May 13, were already covered on May 5. The next identified stock market event is therefore the Bernstein conference on May 21.
Au troisième trimestre, nous avons continué à nous concentrer sur le renforcement de notre trésorerie, ce qui nous a permis de refinancer notre dette à des conditions financières plus avantageuses.
Chiffre d’affaires de 127,0 millions d’euros sur neuf mois (+8,9 %), ventes de 119,4 millions d’euros, trésorerie de 143,5 millions d’euros au 30/09/2025, perte nette 65,2 millions d’euros, EBITDA ajusté (37,7) millions d’euros. Guidance 2025 confirmée : chiffre d’affaires attendu entre 165 et 180 millions d’euros; ventes attendues entre 155 et 170 millions d'euros. Renforcement de la position financière via refinancement et ATMs; Phase 3 VALOR pour le vaccin Lyme en cours selon calendrier.
Risks mentioned
Suspension de la licence IXCHIQ ® aux États-Unis par la FDA (impact sur ventes segment voyageurs)
Risque de résultats cliniques défavorables pour les candidats (phase 3 VALOR pour Lyme, essais S4V2, VLA1601 incertitudes réglementaires)
Exposition aux fluctuations de change (impact négatif mentionné de 1,3 millions d’euros sur ventes, effets de change volontaires)
Dépendance à des partenaires de distribution et diminution des produits de tiers (arrêt de distribution de Rabipur/RabAvert et Encepur)
Opportunities identified
Résultats positifs potentiels de la Phase 3 VALOR (VLA15) pouvant mener à des demandes d'autorisation en 2026
Accord commercial avec CSL Seqirus en Allemagne pour stimuler la commercialisation des vaccins
Croissance des ventes d'IXCHIQ ® sur les marchés hors États-Unis et dans les PRFI (livraisons de substance active)
Potentiel du candidat S4V2 contre la shigellose (marché estimé > 500 millions de dollars/an)
Données positives de Phase 1 pour VLA1601 (Zika) et forte persistance d'anticorps pour IXCHIQ ® (95 % à 4 ans) comme avantage concurrentiel
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
